Combination therapy has, to some extent, been successful in limiting the emergence of drug-
resistant tuberculosis. Drug combinations achieve this advantage by simultaneously acting …

Lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis.
However, we lack well-validated, high-throughput in vitro models that predict animal …

Introduction Tuberculosis requires lengthy multi-drug therapy. Mycobacterium tuberculosis
occupies different tissue compartments during infection, making drug access and …

Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Application of clinical pharmacology best practices is essential to the efficient and rational
development of drugs. In general, knowledge gained about exposure–response …

Combination therapy is necessary to treat tuberculosis to decrease the rate of disease
relapse and prevent the acquisition of drug resistance, and shorter regimens are urgently …

Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

Highlights•Dose selection for new combination therapy in tuberculosis has remained
empirical.•Novel tools are needed for effective translation of preclinical models to humans.•A …

The rapid spread of multidrug-resistant strains has created a pressing need for new drug
regimens to treat tuberculosis (TB), which kills 1.8 million people each year. Identifying new …

Tuberculosis still remains a global health emergency, claiming 1.5 million lives in 2013. The
bacterium responsible for this disease, Mycobacterium tuberculosis (M. tb), has successfully …